{"schema_version":"secwatch.filing_event.v1","accession":"0001517022-24-000067","form_type":"8-K","ticker":"AKBA","cik":"0001517022","company_name":"Akebia Therapeutics, Inc.","filed_at":"2024-10-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.656640+00:00","generated_at":"2026-05-30T13:40:37.406960+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Akebia extends vadadustat supply agreement with STA through 2032","bullets":["Amendment #1 to Supply Agreement with STA extended term to January 1, 2032.","Volume-based pricing structure and other provisions related to vadadustat drug product amended.","Original Supply Agreement entered February 10, 2021 for manufacturing of vadadustat."],"urls":{"canonical":"https://secwatch.observer/filing/0001517022-24-000067","json":"https://secwatch.observer/filing/0001517022-24-000067.json","markdown":"https://secwatch.observer/filing/0001517022-24-000067.md","text":"https://secwatch.observer/filing/0001517022-24-000067.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517022/000151702224000067/0001517022-24-000067-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517022/000151702224000067/akba-20241015.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T13:40:37.406960+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}